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REVIEW
Abstract: Diabetes mellitus is an important risk factor for cardiovascular morbidity and
mortality. The metabolic abnormalities caused by diabetes mellitus induce vascular endothelial
dysfunction that predisposes patients with diabetes mellitus to atherosclerosis. Two mega
clinical trials showed that intensive glycemic control does not have favorable effects on reducing
macrovascular events although it demonstrated significant reductions in microvascular
complications. It is becoming worthwhile to clarify the beneficial effects of tight controls on
blood pressure, serum lipids, and postprandial hyperglycemia to prevent atherosclerosis in
patients with type 2 diabetes mellitus. Here, we focus on vascular endothelium as a target of
the prostaglandin I2 analog beraprost sodium and the peroxisome proliferators-activated
receptor α activator fenofibrate for the prevention and treatment of atherosclerosis in patients
with type 2 diabetes mellitus. Beraprost sodium lowered circulating vascular cell adhesion
molecule-1 (VCAM-1) concentration and prevented the progression of carotid atherosclerosis
in type 2 diabetic patients, probably through inhibiting VCAM-1 expression in vascular
endothelium. Fenofibrate up-regulated endothelial nitric oxide synthase expression, which
may explain its effects to improve endothelium-dependent vasodilatation and to prevent the
progression of coronary atherosclerosis. The approaches to target the molecules expressed in
vascular endothelium will become important for preventing the atherosclerosis in type 2
diabetes mellitus.
Keywords: vascular cell adhesion molecule-1, endothelial nitric oxide synthase, peroxisome
proliferators-activated receptor α, beraprost sodium, fenofibrate
Introduction
Type 2 diabetes mellitus is a syndrome of disordered metabolism with inappropriate
hyperglycemia due to both an absolute deficiency of insulin secretion and a reduction
in the biological effectiveness of insulin. The chronic exposure to high levels of
blood glucose is an important factor leading to diabetic vascular complications.
Diabetes mellitus is an independent risk factor for cardiovascular disease,
cerebrovascular disease, and peripheral vascular disease. According to the Multiple
Risk Factor Interventional Trial (MRFIT), patients with diabetes mellitus are known
to be affected by cardiovascular disease three times as frequently as nondiabetic
subjects, with adjustment for other risk factors (Stamler et al 1993). From the two
mega trial studies with type 1 diabetes mellitus and type 2 diabetes mellitus,
establishing that the intensive glycemic control decreases the incidence of
macrovascular complications has proved much more elusive than the established
beneficial effects on microvascular complications such as retinopathy or renal disease
(Diabetes Control and Complications Trial Research Group 1993; UKPDS 1998a).
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Diabetic macrovascular complications occur by complex
mechanisms consisting of atherosclerosis, thrombosis, and
hemodynamic abnormalities. Among them, atherosclerosis
is an important component for diabetic macrovascular
complications. Thus, understanding the pathophysiology of
atherosclerosis in diabetes mellitus and prevention of
atherosclerotic vascular diseases are clinically important
issues. Vascular endothelial dysfunction is an early event of
diabetic macroangiopathies (Stehouwer et al 1992). A
number of pharmacotherapeutic approaches for correcting
impaired endothelial function, such as antioxidants,
angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists, tetrahydrobiopterin, methytetra-
hydrofolic acid, and arginine, have been investigated (for a
comprehensive review, see Woodman et al 2005). In this
review, we focus on two kinds of reagents targeting vascular
endothelium for the prevention and treatment of
atherosclerosis in patients with type 2 diabetes mellitus: the
prostaglandin (PG) I2 analog beraprost sodium, and the
peroxisome proliferators-activated receptor (PPAR)α
activator fenofibrate.
Hyperglycemia as a target of
antiatherosclerotic therapy in type
2 diabetes mellitus
Macrovascular complications of diabetes mellitus are
postulated as distinct from diabetic microvascular
complications due to their pathophysiology and
epidemiology. It has been shown that a 1% increase in
glycosylated hemoglobin (HbA1c) resulted in a 70%
increase in proliferative retinopathy, but only a 10% increase
in cardiovascular events (Klein 1995). Thus, hyperglycemia
is a dominant risk factor for diabetic retinopathy or diabetic
kidney disease, but it showed not to be the only risk factor
for atherosclerosis in diabetic patients.
In our analysis of 125 type 2 diabetic patients without
microvascular complications, 50% of the patients were
diagnosed as having atherosclerosis of the carotid arteries
based on ultrasonographic evaluation. Risk factors for early
atherosclerosis of the carotid arteries were age, low-density
lipoprotein (LDL)-cholesterol, hypertension, and diabetes
treatment, but neither fasting plasma glucose, HbA1c, nor
known diabetes duration (Goya, Kitamura, et al 2003). These
results indicate that glycemic control estimated by fasting
plasma glucose and HbA1c levels is poorly related to
asymptomatic atherosclerosis in type 2 diabetic patients
without diabetic microvascular complications.
Recent epidemiological studies suggest that postprandial
hyperglycemia may be a risk factor of cardiovascular disease
beyond and more powerful than fasting hyperglycemia
(Bonora and Muggeo 2001). A possible mechanism is that
hyperglycemia after meals causes an overproduction of free
radicals and thrombin proportional to blood glucose levels
in type 2 diabetic patients (Ceriello et al 2002). Moreover,
acute elevation of glucose levels in healthy subjects reduces
nitric oxide (NO) availability (Giugliano et al 1997) and
increases the circulating levels of some cellular adhesion
molecules (Marfella et al 2000). In subjects with normal
glucose tolerance (NGT) and those with impaired glucose
tolerance (IGT), acute hyperglycemia increases circulating
cytokine concentrations by an oxidative mechanism
(Esposito et al 2002). Oral glucose tolerance test (OGTT)-
2 h glucose is an important predictor for plasma high-
sensitivity C-reactive protein level, an associated marker of
cardiovascular disease, in nondiabetic subjects (Hashimoto
et al 2004). It has been reported that reduction of
postprandial hyperglycemia in type 2 diabetic patients is
associated with carotid atherosclerosis regression (Esposito
et al 2004) and cardiovascular events (Hanefeld et al 2004).
Hypertension and dyslipidemia as
targets of antiatherosclerotic
therapy in type 2 diabetes mellitus
To prevent cardiovascular events in patients with type 2
diabetes mellitus, therapeutic strategies that have been
shown by clinical trials include antihypertensive therapy,
lipid-lowering therapy, and antiplatelet therapy.
The tight control of blood pressure has been shown to
reduce the incidence of deaths related to diabetes, stroke,
diabetic microvascular endpoints, progression of diabetic
retinopathy, and deterioration in visual acuity (UKPDS
1998b). However, there was no significant reduction in all
cause mortality and myocardial infarction in that study, but
the study was not powered to detect moderate changes in
these parameters. By contrast, subanalysis of the
Hypertension Optimal Treatment (HOT) study showed that
intensive lowering of diastolic blood pressure was associated
with significant reductions in cardiovascular events in
diabetic patients, although it failed to demonstrate the
beneficial effects of tight blood pressure control on the
prevention of myocardial infarction and stroke (Hansson et
al 1998).
There is a substantial group of type 2 diabetes
patients in whom the levels of both plasma triglyceride andVascular Health and Risk Management 2005:1(3) 211
Vascular endothelium as a target of beraprost and fenofibrate
LDL-cholesterol are elevated and with low high-density
lipoprotein (HDL) cholesterol. Treatment with the statin
class of lipid-lowering drugs (HMG-CoA reductase
inhibitors) efficiently corrects the elevated LDL-cholesterol
level. In the Anglo-Scandinavian Cardiac Outcomes Trail-
Lipid Lowering Arm (ASCOT-LLA), atorvastatin could not
reduce the risk of nonfatal myocardial infarction and
coronary artery heart disease death in patients with diabetes
and hypertension who had no preexisting coronary heart
disease, although LDL-cholesterol level in the atorvastatin
group was 1.2 mmol/L lower than the placebo group (Sever
et al 2003). The Heart Protection Study (HPS),which
included 5963 patients with diabetes who were prospectively
randomized to treatment with simvastatin or placebo,
demonstrated 27% decrease (p = 0.0007) in major coronary
events with active treatment (Collins et al 2003). In the
Collaborative Atorvastatin Diabetes Study (CARDS)
(Colhoun et al 2004), 2838 patients with type 2 diabetes
mellitus were studied. A significant 37% reduction in
cardiovascular events was shown in the atorvastatin group.
Overall, some but not all studies have reported significant
reduction in coronary heart disease risk with statin therapy
in diabetic patients (Garg 2004). Statin therapy is shown to
have the ability to improve insulin resistance in dyslipidemic
type 2 diabetic patients (Paolisso et al 2000) and endothelial
function through increasing the bioavailability of NO
(Wolfrum et al 2003). Improvement of flow-mediated
dilatation (FMD) after atorvastatin treatment for 6 months
has been demonstrated in type 2 diabetic patients (Tan et al
2002), although there have been reports of controversial
results with the use of atorvastatin or simvastatin (Sheu et
al 1999; van Etten et al 2002). Thus, the beneficial effect of
statins on cardiovascular diseases may be at least in part
mediated by improving vascular function, in addition to the
effect of controlling dyslipidemia.
The fibric acid derivative fenofibrate significantly
reduced the angiographic progression of coronary artery
disease in type 2 diabetes mellitus (Diabetes Atherosclerosis
Intervention Study Investigators 2001). The favorable effect
of fenofibrate on coronary artery disease is indicated to be
exerted by increasing the expression of ApoA-I and ApoA-
II as well as by increasing LDL particle size (Vakkilainen
et al 2003). Additionally, since fenofibrate has the ability to
activate PPARα more specifically than other fibrates such
as gemfibrozil and bezafibrate (Keating and Ormrod 2002),
the effects of fenofibrate also may be mediated through
pleiotropic effects improving endothelial function, which
will be shown later.
Multifactorial intervention that targeted hyperglycemia,
hypertension, dyslipidemia, and microalubuminuria, along
with secondary prevention of cardiovascular disease with
aspirin, in patients with type 2 diabetes and micro-
alubuminuria, has been recently shown to reduce the risk of
cardiovascular and microvascular events by about 50%
(Gaede et al 2003).
Adhesion molecules expressed in
endothelium as targets of
antiatherosclerotic therapy in type
2 diabetes mellitus
Atherosclerosis is characterized by endothelial cell injury,
which in turn leads to mononuclear cell adhesion to the
endothelium, the initial migration and proliferation of
smooth muscle cells, and extracellular matrix deposition
(Ross 1999). Various adhesion molecules, such as vascular
cell adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1), E-selectin, and platelet endothelial
cell adhesion molecule (PECAM) have been shown to be
highly expressed in atherosclerotic lesions, which might be
involved in mononuclear cell adhesion to the vascular
endothelium (Cybulsky and Gimbrone 1991; O’Brien et al
1993; Bevilacqua et al 1994). It has been shown that
circulating VCAM-1 level is correlated with early
atherosclerosis in patients with type 2 diabetes mellitus
(Figure 1) (Otsuki et al 1997). The Hoorn study
demonstrated that elevated circulating VCAM-1 level is
independently associated with an increased future risk of
cardiovascular mortality in type 2 diabetes mellitus (Jager
et al 2000). Thus, to inhibit the VCAM-1 expression on the
vascular endothelium may be a strategy for preventing
Figure 1 Relationship between serum circulating vascular cell adhesion
molecule (VCAM)-1 and mean intima-medial thickness (mIMT) of carotid
arteries in 101 patients with type 2 diabetic mellitus.
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occurrence and progression of atherosclerosis in patients
with type 2 diabetes.
VCAM-1 expression is enhanced by various inflam-
matory molecules such as tumor necrosis factor (TNF)-α
and interleukin (IL)-1. The expression of VCAM-1 is known
to be inhibited by various reagents such as glucocorticoids
(Simoncini et al 2000), estrogen (Caulin-Glaser et al 1996;
Simoncini et al 1999), progestins (Otsuki et al 2001), retinoic
acid (Gille et al 1997), and fibric acid derivatives (Marx et
al 1999; Xu et al 2001).
We recently found that beraprost sodium, orally active
PG I2 analog, also efficiently inhibited TNF-α-induced
VCAM-1 expression in human vascular endothelial cells
(Figure 2a) (Goya, Otsuki, et al 2003). Beraprost also
decreased the number of human monocytoid cells adhesion
to vascular endothelial cells (Figure 2b). In our clinical study
on 25 type 2 diabetic patients who had atherosclerotic
change of carotid arteries, the 3-year changes of circulating
VCAM-1 level were significantly lower in patients receiving
beraprost sodium than those not receiving it (Figure 3). The
3-year changes of common carotid artery (CCA) intima-
medial thickness (IMT) were also significantly lower in
those with the beraprost treatment. Studies of 10 patients
who could be followed up for 8 years with beraprost
treatment showed that their CCA IMT was not significantly
changed from 1.17 ± 0.24 mm (SE) to 1.13 ± 0.19 mm after
8 years (Figure 4). During this course, body mass index,
fasting glucose, HbA1c and total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglycerides were not
significantly changed in these patients. Based upon the data
of the Insulin Resistance Atherosclerosis Study
(Wagenknecht et al 2003), the average CCA IMT
progression reported 0.0072 mm per year in persons with
diagnosed diabetes, corresponding to the increases of
0.056 mm in 8 years. Although these data cannot be simply
compared with our results shown in Figure 4, beraprost may
be effective long-term for the inhibition of atherosclerosis TNF-D +
-
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Figure 2 (a) Effect of beraprost on cell surface VCAM-1 level in vascular
endothelial cells. Vascular endothelial cells were treated for 15 minutes with or
without the indicated concentrations of beraprost, and then the cells were
stimulated with (hatched bars) or without (open bars) 0.1 ng/mL TNF-α for 2
hours. Cell surface VCAM-1 was determined by whole cell ELISA. Data are
means ± SE. *p < 0.001 vs TNF-α only, by ANOVA.
(b) Effects of beraprost on U937 cell adhesion to TNF-α-stimulated vascular
endothelial cells. Vascular endothelial cells were treated for 15 minutes with or
without 10
–5 mol/L beraprost and then stimulated with or without 0.1 ng/mL
TNF-α for 2 hours. Data are means ± SE. Abbreviations: ANOVA, analysis of
variance; ELISA, enzyme-linked immunoabsorbent assay; OD, optical density; TNF,
tumor necrosis factor; VCAM, vascular cell adhesion molecule.
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Figure 3 Changes in circulating vascular cell adhesion molecule (VCAM-1) level
(a) and mean intima-medial thickness (mIMT) of common carotid arteries (b) in
25 patients with type 2 diabetes mellitus receiving (n = 11) or not receiving
(n = 14) beraprost for 3 years. Data are means ± SE.
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progression in type 2 diabetes. The sum total of these
observations provides the potential of beraprost sodium as
an antiatherosclerotic drug in type 2 diabetic patients, at
least partly through inhibiting VCAM-1 expression in
vascular endothelium.
It has been shown that PPARα activators fenofibrate and
WY14643 inhibited cytokine-induced VCAM-1 expression,
resulting in inhibition of leukocyte adherence on vascular
endothelial cells (Marx et al 1999). These observations
indicate implications regarding the clinical use of the fibrate
class of lipid-lowering agents. Although one clinical study
of 11 patients with type 2 diabetes showed no significant
change in plasma VCAM-1 concentrations by fenofibrate
treatment for 6 weeks (Empen et al 2003), a larger cohort
study should be investigated.
Endothelial nitric oxide synthase
(eNOS) expressed in endothelium
as a target for antiatherosclerotic
therapy in type 2 diabetes mellitus
Endothelium-derived NO is a potent mediator with
antiatherogenic properties such as stimulation of vaso-
relaxation and repression of endothelial leukocyte adhesion
molecules, platelet aggregation, and smooth muscle cell
proliferation. Endothelial dysfunction due to impaired
production and/or action of NO occurs in the early stages
of atherosclerosis caused by various risk factors such as
hypercholesterolemia (Creager et al 1990), hypertension
(Panza et al 1990), cigarette smoking (Celermajer et al
1993), aging (Celermajer, Sorensen, Spiegelhalter, et al
1994), male sex (Celermajer, Sorensen, Bull, et al 1994),
and hyperhomocystinemia (Woo et al 1997). Impairment
of NO production and its action has also been demonstrated
in patients with diabetes mellitus (Jonhnstone et al 1993;
Williams et al 1996; Beckmann et al 2002). NO is produced
from L-arginine by eNOS. Endothelium-derived NO is
responsible for FMD (Joannides et al 1995). The FMD of
the brachial artery, a parameter of endothelium-dependent
vasodilatation, is significantly lower in patients with type 2
diabetes than normal control subjects (Williams et al 1996;
Meeking et al 1999). Thus, to increase eNOS expression in
endothelium may be a potential antiatherogenic target in
diabetic patients.
Recent clinical studies have shown that the fibric acid
derivative fenofibrate improved vasodilator function.
Playford et al (2002) showed that fenofibrate significantly
improved brachial artery FMD, but not nitroglycerin-
mediated dilatation in patients with type 2 diabetes.
Fenofibrate significantly increased forearm blood flow in
response to acetylcholine, nitroprusside, or verapamil in
patients with hypertriglyceridemia (Capell et al 2003). These
results indicate that fenofibrate can improve both
endothelium-dependent and endothelium-independent
vasodilatation. We have shown that fenofibrate and
WY14643, also able to activate PPARα, up-regulated eNOS
expression in vascular endothelial cells (Goya et al 2004).
Bezafibrate, a fibrate drug that potentially activates three
types of PPAR (PPARα, -γ, -δ), also increased eNOS
expression, whereas rosiglitazone, a specific ligand for
PPARγ, failed to increase eNOS expression. Taken together
with our result that RU486, shown to have a potential to
antagonize PPARα, inhibited the fenofibrate-induced up-
regulation of eNOS expression, the fenofibrate-induced up-
regulation of eNOS expression was mediated through
PPARα. Analysis of the human eNOS promoter sequence
(–1600 to +22 nucleotides) did not contain any discernible
PPAR response element, and transient transfection of the
eNOS promoter construct showed that fenofibrate failed to
increase its promoter activity. In addition, the experiments
using the transcriptional inhibitor actinomycin D showed
that fenofibrate stabilized eNOS mRNA (Figure 5). These
data also suggest direct effects of the fibrates on vessel wall
for cardiovascular protection besides lipid-lowering effects.
We will see in the near future the results of a large trial that
is currently examining the effect of fenofibrate on
cardiovascular mortality in patients with type 2 diabetes
mellitus (Fenofibrate Intervention and Event Lowering in
Diabetes [FIELD] study).
Figure 4 Changes in mean intima-medial thickness (mIMT) of common carotid
arteries in 10 patients with type 2 diabetes mellitus treated with beraprost for 8
years. Data are means ± SE. p = 0.44, by ANOVA (analysis of variance).
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Conclusion
Atherosclerosis in type 2 diabetes mellitus has been hard to
overcome. Multifactorial therapies targeting hyperglycemia,
blood pressure, and lipids have proven efficient for reducing
cardiovascular events. However, it still remains unclear
whether such combination therapy is the best of
antiatherosclerotic therapies for type 2 diabetes mellitus, in
terms of safety or cost-effectiveness. Here, we demonstrated
the potentials of the PGI2 analog beraprost and the PPARα
activator fenofibrate to target VCAM-1 and eNOS,
respectively, in vascular endothelium. These drugs may be
added to the lists of antiatherosclerotic modalities for type
2 diabetes.
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